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Abstract Germ-line mutations in BRCA1 breast cancer
susceptibility gene account for a large proportion of
hereditary breast cancer families and show considerable
ethnic and geographical variations. The contribution of
BRCA1 mutations to hereditary breast cancer has not yet
been thoroughly investigated in Middle Eastern and North
African populations. In this study, 16 Tunisian high-risk
breast cancer families were screened for germline muta-
tions in the entire BRCA1 coding region and exon–intron
boundaries using direct sequencing. Six families were
found to carry BRCA1 mutations with a prevalence of
37.5%. Four different deleterious mutations were detected.
Three truncating mutations were previously described:
c.798_799delTT (916 delTT), c.3331_3334delCAAG
(3450 delCAAG), c.5266dupC (5382 insC) and one splice
site mutation which seems to be speciﬁc to the Tunisian
population: c.212 ? 2insG (IVS5 ? 2insG). We also iden-
tiﬁed 15 variants of unknown clinical signiﬁcance. The
c.798_799delTT mutation occurred at an 18% frequency
and was shared by three apparently unrelated families.
Analyzing ﬁve microsatellite markers in and ﬂanking the
BRCA1 locus showed a common haplotype associated with
this mutation. This suggests that the c.798_799delTT
mutation is a Tunisian founder mutation. Our ﬁndings
indicate that the Tunisian population has a spectrum of
prevalent BRCA1 mutations, some of which appear as
recurrent and founding mutations.
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Introduction
Breast cancer is the most common cause of cancer-related
death among women worldwide with an estimated 1.15
million new cases and 411,000 breast cancer deaths around
the world in 2002 [1, 2]. Breast cancer incidence has
increased progressively in Middle Eastern and North
African (MENA) populations over the last 10 years,
probably due to more reliable data being collected from
cancer registries and to easier access by patients to
screening and diagnostic programs [3]. In MENA popula-
tions, breast cancer represents *13–30% of newly diag-
nosed malignancies in women and occurs at a median age
of 49–52 years as compared to 63 in industrialized nations
[3–12]. Breast cancer in MENA populations is character-
ized by younger age at onset, advanced stage and poor
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DOI 10.1007/s11033-011-0829-8prognosis [3–12]. Mastectomy is performed in more than
80% of MENA women with breast cancer [3].
Comparison of the clinical and tumor gene expression
proﬁles of breast cancer between French and MENA
patients showed minor but signiﬁcant biological differ-
ences. A signiﬁcant difference has been found in breast
cancer diagnosis age (±10 years old) between French and
MENA patients. This difference was more marked in
Tunisian patients with a more than 13-year-old diagnosis
difference. Moreover, a higher frequency of aggressive
tumors was found among MENA patients as deﬁned by the
SBR histo-prognostic grade III, tumor size at diagnosis and
lymph node metastasis [13].
Breast cancer is an extremely complex, heterogeneous
and multi-factorial disease characterized by a progressive
multistep process caused by interactions of both genetic
and non-genetic factors. A family history of breast cancer
is the most prominent risk factor for the development of the
disease [14]. It is estimated that about 5–10% of all breast
cancers may arise from hereditary predisposition [15, 16].
Investigation of multiple-case families in which breast
cancer segregates with mendelian patterns of inheritance
led to the identiﬁcation of the tumor suppressor genes
BRCA1 (MIM 113705) [17] and BRCA2 (MIM 600185)
[18], which account for a substantial proportion of early-
onset breast cancer but a much smaller proportion of late-
onset disease [19, 20]. Germ-line BRCA1 mutations are
involved in about 30% of site-speciﬁc female breast cancer
families, 75% of breast/ovarian cancer families, but not in
male breast cancer families [21–23]. Germ-line BRCA2
mutations are involved in about 30% speciﬁc female breast
cancer families, 20–25% of breast/ovarian cancer families,
and 50–80% of male/female breast cancer families [19, 20,
22–24]. These ﬁgures are deduced from studies on Euro-
pean and American populations and they are expected to be
different for other populations. Cumulative risk of cancer
in BRCA germ-line mutated carriers is highly dependant on
the mutation type, the genetic background and acquired
environmental factors. Life-time cumulative cancer risk in
BRCA1 mutation carriers is about 80–85% for female
breast cancer, 50% for ovarian cancer, 12–40% for bilat-
eral breast cancer [19, 25–28]. Life-time cumulative cancer
risk in BRCA2 mutation carriers is about 80–85% for
female breast cancer (with a later breast cancer onset),
10–25% for ovarian cancer, 6–10% for male breast cancer
[19, 23–28].
The frequency and spectrum of mutations within
BRCA1/2 genes vary widely among populations. In some
ethnic or geographically isolated groups, founder mutations
can explain the majority of inherited breast and ovarian
cancer cases [29–32], whereas in other populations, germ-
line mutations are randomly scattered throughout the cod-
ing sequence [33].
The analysis of the BRCA1/2 genes as well as other
genes conferring increased risk of hereditary breast cancer
(e.g. TP53, PTEN, STK11, CDH1) was poorly studied in
the MENA populations. Few reports, including from our
group, reported few BRCA1/2 mutations associated with
hereditary breast cancers in a small number of families
from MENA countries [34–39].
The aim of this study was to investigate the mutational
spectrum and frequency of germ-line BRCA1 mutations as
well as to explore the existence of population-speciﬁc
recurrent or founder mutations, if any, in Tunisian breast
cancer families.
Patients and methods
Patients and families
The current study was conducted on breast cancer families
in the middle coast of Tunisia with the cooperation of two
main cancer treatment centers in Sousse, Tunisia: depart-
ments of Radiation Oncology and Medical Oncology of
Farhat Hached teaching Hospital, Sousse, Tunisia.
Selection criteria of familial cases were based on age at
diagnosis and the number of affected ﬁrst- and second-
degree relatives with breast or ovarian cancer. These fam-
ilies’ characteristics are presented in Table 1. The inclusion
criteria were (i) Three or more breast and/or ovarian cancers
in ﬁrst or second degree relatives one of which developed at
an early age\35 years or (ii) two cases with young age at
diagnosis (\35 years) and/or bilateral breast cancers and/or
multiple cancers including ovarian and breast cancers.
Blood samples were taken from at least one affected woman
from each family. Twenty-four patients belonging to 16
families were recruited. One family presented a case of
ovarian cancer and no families with male breast cancer were
found. All families were apparently unrelated. Written
informed consent was obtained from all subjects. Ethics
committee approval was obtained from Weill Cornell
Medical College in Qatar and from Farhat Hached teaching
hospital of Sousse in Tunisia.
Methods
Genomic DNA was extracted from peripheral blood leu-
kocytes using the standard salting out procedure [40]. As
for mutation screening, the BRCA1 gene coding region and
exon–intron boundaries were analyzed using direct DNA
sequencing. The exons were ampliﬁed in 20 ll with 100 ng
DNA, 19 reaction buffer, 200 lM dNTPs, 1.5 mM MgCl2,
0.8 lM primers (designed by Centre Jean Perrin, sequences
available on request) and 1 unit Taq polymerase (except
primers, all other reagents from Promega, France). PCR
1038 Mol Biol Rep (2012) 39:1037–1046
123was performed in an thermocycler (Biometra, Germany)
with an initial denaturation at 94C for 5 min, followed by
30 cycles of (94C2 0s ,5 4 C2 0s ,7 2 C 20 s), except for
exon 7 (15 cycles of 94C2 0s ,6 0 C1 0s ,7 2 C 20 s then
25 cycles of 94C2 0s ,5 6 C1 5s ,7 2 C 20 s) and 23
(5 cycles of 94C2 0 s ,5 7 C2 0 s ,7 2 C 20 s then
30 cycles of 94C2 0s ,5 3 C2 0s ,7 2 C 20 s). Exon 11
was analysed in nine overlapping PCR fragments. After
ampliﬁcation, the PCR products were subjected to elec-
trophoresis in a 2% agarose gel. The product was cut from
the gel and puriﬁed using QIAquick gel extraction kit
(Qiagen, CA). Both DNA strands were sequenced using
BigDyeDeoxy terminator cycle sequencing kit (BD V3.1,
Applied Biosystems) according to the manufacturer’s
instructions. The product was puriﬁed on a separation
column (AutoSeq
TM G-50, Amersham Biosciences), and
the templates were sequenced on an automated ABI-
PRISM 310 Genetic Analyzer (Applied Biosystems).
Sequence analysis was performed using Seqman software
(DNAstar, Madison, WI).
Results
In the current study, the whole BRCA1 gene screening was
carried out on 24 patients belonging to 16 unrelated high-
risk breast cancer families from the middle coast of Tunisia.
These families’ characteristicsarepresentedinTable 1.The
median age of onset disease was 41 years, range 29–65.
Twenty-three cases were diagnosed with site-speciﬁc
breast cancer and one with bilateral breast cancer. BRCA1
genemutationanalysiswasperformedinthesecases.BRCA1
gene’s entire coding region and its exon–intron boundaries
were examined by direct sequencing.
Our results revealed six breast cancer families carrying
deleterious BRCA1 mutations with a frequency of 37.5% (6/
16). In this study, a total of 19 alterations were identiﬁed in
the BRCA1 gene. An overview of the mutational spectrum is
listedinTable 2withboththeHumanGenomeOrganization
(HUGO) approved systematic nomenclature and the Breast
Cancer Information Core (BIC) traditional nomenclature.
Four distinct deleterious BRCA1 mutations were iden-
tiﬁed. Three are frame-shift mutations including two small
deletions (c.798_799delTT, c.3331_3334delCAAG) and
one small insertion (c.5266dupC), all resulting in frame-
shifts that cause premature protein termination at codon
285, 1115 and 1829, respectively. The fourth mutation was
an intron 5 splice site insertion (c.212 ? 2insG). The 15
remaining identiﬁed variants were missense (11), silent (3)
and intronic (1) mutations classiﬁed as polymorphisms or
unknown variants in the BIC database (Table 2). Among
these variants three were unique (observed only once):
(F486L), c.1648A/C (N550H) and c.5117 G/C (G1706A).
Among the 19 BRCA1 alterations detected in our study,
the splice site mutation (c.212 ? 2insG) has not been
reported previously in the BIC database and is therefore
considered to be novel. The deleterious mutations were
Table 1 Families’ characteristics of our cohort
Family
ID
Sex of
proband
Phenotype and
age at diagnosis
Family history of breast and ovarian
cancers and age at diagnosis
Family history of
other cancers
F1 Female Br30 M Br 35, PC Br 35 Leukemia
F2 Female Br 34 S Br 20 Leukaemia
F3 Female Br 34 MA Br 45, MA Br ? None
F4 Female Br 35 MA Br 50, GM Br? Brain
F5 Female Br 46 S Br 42, M Br 65 None
F7 Female Br 36 S Br 40, M Br ?, GM Br 50 None
F8 Female BBr 38 M Br 38, S Br 43 None
F9 Female Br 42 S Br 35 Prostate
F10 Female Br 34 M Br33 None
F11 Female Br 53 S Br 40, S Br 60 None
F12 Female Br 29 S Br 39 None
F13 Female Br 61 S Br 28 None
F14 Female Br 47 S Br 35, N Br 30 Cervical, liver
F15 Female Br 42 M Br 40 None
F16 Female Br35 M Br?, MA Br? Colon
F17 Female Br 49 MA Br 52, MA Br 68, PC Br 42,
PC Br 35, PC Ov 62
Colon, Nasopharynx
Br breast cancer, BBr bilateral breast cancer, OV ovarian cancer, M mother, S sister, GM grand-mother, MA maternal aunt, PC paternal cousin,
N Niece
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123located only in three exons of BRCA1 gene with one
mutation in exon 5 (c.212 ? 2insG), two mutations in exon
11 (c.798_799delTT, c.3331_3334delCAAG) and one
mutation in exon 20 (c.5266dupC).
The c.798_799delTT was shared by three apparently
unrelated families and it accounted for 3 of the 16 (18%)
BRCA1 mutated families. The remaining mutations, includ-
ingc.3331_3334delCAAG,c.5266dupCandc.212 ? 2insG,
were unique (i.e., each one was detected only in one family).
FromthesixfamilieswithBRCA1mutations,three(50%)
had three breast cancer cases. The remaining three families
(50%) had two cases of early-onset breast cancer, with a
diagnosis age being B35 years. Five of these were families
with site-speciﬁc breast cancer, and only one was a bilateral
breast cancer family. The median age of onset disease was
42 years (ranged from 34–65) and 40 years (ranged from
29–61) among carriers and non-carriers, respectively.
Discussion
The prevalence and spectrum of BRCA1 mutations among
Middle-Eastern and North African (MENA) breast and
ovarian cancer families have not yet been thoroughly
studied [39, 41]. In the current study, we have screened the
BRCA1 gene in a cohort of 16 high-risk breast cancer
families from the middle-coast of Tunisia. Interestingly,
the prevalence is higher and the mutation spectrum is dif-
ferent as we observed only one of the four previously
reported mutations [41].
BRCA1 mutations were identiﬁed in six families of our
cohort with a notable 37.5% frequency. Four distinct del-
eterious BRCA1 mutations were identiﬁed in our study:
c.798_799delTT c.3331_3334delCAAG, c.5266dupC and
c.212 ? 2insG.
The c.798_799delTT was the most commonly observed
mutation. It was shared by ﬁve patients belonging to
three apparently unrelated families (F2, F8 and F10). It
accounted for 3 of the 16 (18%) BRCA1 mutated families.
First, this mutation was detected in two unrelated patients
belonging to families F2 and F10 with site-speciﬁc breast
cancer. The same mutation was also observed in two
Algerian families [39]. Analyzing ﬁve microsatellite
markers in and ﬂanking the BRCA1 locus showed a com-
mon haplotype associated with this mutation in these four
carriers (data not shown) [39]. Then this mutation was
targeted and found in family 8. The index case, diagnosed
with bilateral breast cancer at the age of 38 years, was a
carrier of the c.798_799delTT mutation. In this family the
mutation co-segregates with the disease and the same
mutation was identiﬁed in the proband’s mother and sis-
ter diagnosed with breast cancer at ages 38 and 43,
respectively (Fig. 1). These ﬁndings suggest that the
c.798_799delTT mutation is a Tunisian and North African
Table 2 BRCA1 Germline
mutations identiﬁed in a cohort
of 16 breast cancer families
from the middle coast of Tunisia
Exon/intron Systematic
nomenclature
BIC traditional
nomenclature
Amino acid change Mutation type
Deleterious mutations
11 c798_799delTT 916delTT Stop285 Frameshift
11 c3331_3334delCAAG 3450delCAAG Stop1115 Frameshift
20 c.5266dupC 5382insC Stop1829 Frameshift
5 c.212 ? 2insG IVS5 ? 2insG – Splicing
Sequence variants of unknown signiﬁcance
8 c.442-58delT IVS8-58delT – Intronic variant
11 c.1067 A[G 1186A[G Q356R Missense
11 c.1456 T[C 1575T[C F486L Missense
11 c.1648A[C 1767A[C N550H Missense
11 c.2077 G[A 2196G[A D693N Missense
11 c.2082C[T 2201C[T S694S Silent
11 c.2311 T[C 2430T[C L771L Silent
11 c.2529C[T 2640C[T R841W Missense
11 c.2612C[T 2731C[T P871L Missense
11 c.3113A[G 3232A[G E1038G Missense
11 c.3119A[G 3238A[G S1040N Missense
11 c.3548C[T 3667A[G K1183R Missense
13 c.4308T[C 4427T[C S1436S Silent
16 c.4837A[G 4956A[G S1613G Missense
18 c.5117 G[C 5236G[C G1706A Missense
1040 Mol Biol Rep (2012) 39:1037–1046
123founder mutation. It has been cited four times in the BIC
database but only once referring to a Spanish origin
(Galician). To our knowledge, it has been reported in two
breast-ovarian cancer families from northeastern France
[42] and also in two breast-ovarian cancer families from
southern Italy (Sicily) [43]. Recently, it has been identiﬁed
in three unrelated families from the middle and south
Sardinia area with many Phoenician and Carthaginian
archaeological sites [44]. This restricted geographical dis-
tribution of the c.798_799delTT mutation in these close
Mediterranean countries may suggest a common founder
ancestor.
The c.5266dupC mutation in BRCA1 exon 20 is the
second most frequently reported mutation in the BIC
database. Though often referred to as a Jewish founder
[45], this mutation is very prevalent in Central and Eastern
Europe with a high frequency among different ethnic
populations such as Poland (*34%) [46], Russia (14%)
[31], Greece (31%) [47] and Brazil [48]. Studies using
genetic markers suggest that the same haplotype is shared
by 5382insC mutation carriers and have placed the origin
of the mutation back to approximately 36 generations, in
the Middle Ages, somewhere in the Baltic area [49–51].
More recent data support origin from a single common
ancestor [52]. In our study, the c.5266dupC mutation has
been found only once in a breast cancer family. The same
mutation was additionally identiﬁed in a Tunisian family
with a history of breast and ovarian cancer [41], which
suggests this mutation contributed to both breast and
ovarian phenotype in the Tunisian population. Having been
detected in two unrelated families, it has a prevalence of
4% (2/48) in the mutation spectrum of BRCA1 gene.
Altogether, our cumulative results suggest that c.5266dupC
is also a potential recurrent mutation and may be one of the
founder effects in the Tunisian population. Further studies
will be necessary in order to estimate more accurately the
population allele frequency and distribution of this muta-
tion among Tunisians. Further haplotype studies of all the
carriers are required to ﬁnd out whether the c.5266dupC
identiﬁed in our population has a common ancestor with
the European mutation or whether high-frequency alleles
have arisen independently more than once.
The identiﬁcation of these founder and recurrent muta-
tions in the population is an extremely important step
towards the improvement of genetic counselling since
molecular testing can be targeted to the founder and
recurrent mutations allowing for a more rapid and less
expensive test. Furthermore, families sharing identical
mutations will make up a genetically homogenous sub-
group allowing more signiﬁcant studies of their clinical
expression.
In our set, the c.3331_3334delCAAG frame shift muta-
tion is found in one family with a 6% frequency. According
to data from the BIC database, this mutation has been cited
40 times mainly with Western European, Caucasian eth-
nicities but only in two families of Latin American/Carib-
bean ancestry and one family with Egyptianethnicity (BIC).
It has been reported to occur in Spain, Portugal [53, 54],
Australia,Canada,SouthAmerica(Chileanpopulation)[55]
and it is also a founder mutation in Hispanic families from
Colombia [56] (BIC). These observations raise the question
whether BRCA1: c.3331_3334delCAAG is an ancient
mutation that has arisen once, or has occurred several times
in human history. The large geographical distribution of this
mutationcouldsuggestindependentoriginsasdemonstrated
for the 4184del4 BRCA1 mutation reported to have at least
three independent origins [50]. A similar ﬁnding was
observed for the 1135insA BRCA1 mutation that does not
have a single origin and was found to occur in three distinct
haplotype backgrounds [57]. This suggests that 4184del4
and 1135insA mutations may have appeared independently
several times in the human genome and may therefore be
relative ‘‘hot spots’’ within the BRCA1 gene [50, 57], this
may also be the case for the c.3331_3334delCAAG muta-
tion. Because of the complexity of the genomic structure of
BRCA1 and the scattering of the mutations throughout the
Family 8
1 2 3 4
38
56 7 8 9 1 0 1 1 1 21 3
years
14 15 16 17
38
years 43
years
15 16 17
I
I I
I I I
Fig. 1 Pedigree of the family 8.
Blackened circles indicate
women affected with breast
cancer. The proband was
designed by an arrow. The
index case, diagnosed with
bilateral breast cancer at the age
of 38 years, was a carrier of the
c.798_799delTT mutation. In
this family the mutation co-
segregates with the disease and
the same mutation was
identiﬁed in the proband’s
mother and sister diagnosed
with breast cancer at ages 38
and 43, respectively
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123gene, a screening of the whole sequence is necessary and
still remains a serious technical challenge especially in
developing countries. For that reasons a ‘‘pre-screen’’ based
on the most frequent BRCA1 mutations seen in the BIC
could be considered as a ﬁrst step, prior to complete gene
sequence analysis [57].
The c.798_799delTT, 5266dupC and c.3331_3334del-
CAAG mutations have been reported in different popula-
tions. The identiﬁcation of these mutations in Tunisian
patients can be explained by the widespread allelic heter-
ogeneity arising from the several different colonizations
that Tunisia underwent through history especially because
of its location at the northernmost bulge of Africa to mark
the division between the eastern and western Mediterra-
nean Sea. It is highly conceivable that these mutations
could have migrated to Tunisia and their introduction in
our population might have some speciﬁc historical origins.
Further genealogical studies can trace the origins of these
mutations and deﬁne exactly when and how they were
introduced into the Tunisian population. Determining the
origins of our identiﬁed mutations may be a helpful crite-
rion in identifying high-risk women regarding their origins
or ethnic background.
The c.212 ? 2insG mutation has not been described in
the BIC database and to our knowledge has not been
reported in any other population studies so far. Therefore, it
is considered to be novel. In general, splice-site alterations
lead to skipping of the complete exon following the
acceptor or preceding the donor site in which the mutation
is located.
For genetic counseling purposes, it is extremely
important to differentiate between deleterious and poly-
morphic splice-site alterations. Analysis at the mRNA level
will allow us to identify whether this variant leads to an
aberrant splicing and can contribute to a correct and
deﬁnitive clinical interpretation.
Apart from the deleterious mutations, we have also
identiﬁed 15 BRCA1 variants classiﬁed as polymorphisms
or variants with unknown signiﬁcance (Table 2). These
variants are known to occur worldwide and in populations
from various geographical areas. Among these 15 variants,
only Q356R and F486L were not described in our previous
study [41]. Three were unique: F486L, N550H and
G1706A (observed only once). Interestingly, in the present
study, the F486L and N550H variants were only identiﬁed
in a healthy woman belonging to F17 family. The associ-
ation of the Y179C, F486L and N550H variants together in
cis with breast cancer has been suggested by Augello et al.
with similar cases in Sicilian and Spanish patients [43, 58,
59]. In our set, the Q356R variant, not described in the
previous study, occurred with a 16% frequency. Dunning
et al. reported that the BRCA1Arg356 allele has a higher
genotype distribution in healthy controls than in breast
cancer patients and may thus play a protective role in
breast cancer [60]. A recent study has also reported similar
ﬁndings [61]. These ﬁndings need deeper investigations.
Further studies are required to compare their frequencies in
cases and controls and thus ﬁnd out whether some variants
or haplotypes are breast cancer risk modiﬁers.
TheprevalenceofBRCA1mutationsreportedinourstudy
(37.5%)isapproximately2.5 times higherthan thatreported
initially (15.6%) [41]. Furthermore, the two spectra emerg-
ing from screening in families from the northern and central
partsofTunisiaarenotstringentlysimilar.Thissuggeststhat
signiﬁcant differences in the frequency and spectrum of
BRCA1 mutations between the different regions of the
country cannot be excluded. However, the higher detection
rate observed in the present study (37.5%) can be partly
explainedbytheexistenceofthefoundermutation.Tobetter
deﬁne the true BRCA1 mutations frequency and spectrum in
the Tunisian population, we extended the study up to 48
families by combining our data with our previously pub-
lished results involving 32 families which were recruited in
the same manner and selected usingthe same criteria as here
[41]. As a result, a cumulative mutation analysis from these
48 Tunisian breast/ovarian cancer families demonstrated
deleterious BRCA1 mutations in 11 families with a notable
frequency of 23% (11/48). Altogether, seven different del-
eterious mutations were detected in the BRCA1 gene. It is
noteworthythat allfound mutationsare located onlyinthree
exons of BRCA1 (exons 5, 11 and 20). Moreover, more than
half (57%) of the identiﬁed mutations are located in exon 11
which spans 60% of the entire BRCA1 coding sequence.
Because of the scattering of the BRCA1 mutations through-
out the gene, a screening of the whole sequence is necessary
but still remains a serious technical challenge especially in
developing countries. In Tunisia, in the future planning for
the effective population screening, a pre-screening of these
three exons could be considered as a ﬁrst step, prior to
complete the whole sequence analysis. Mutation screening
can be performed by different techniques which are less
laborious and expensive than direct sequencing. The most
used techniques are DHPLC (Denaturing High Performance
Liquid Chromatography), PTT (Protein Truncation Test)
and SSCP (Single Strand Conformational Polymorphism)
[44, 47, 56, 59].
Unlike the spectra observed in genetically homogenous
populations such as Iceland, Norway and Poland, the het-
erogeneous BRCA1 mutation spectrum observed in our
series of families is consistent with the genetic heteroge-
neity and ethnic diversity of the Tunisian population and
also may reﬂect the existence of multiple distinct founders.
For the likelihood of having BRCA1 mutations, two
criteria are of importance: age at diagnosis, and the number
and types of cancer in the family. To establish the best
criteria in selecting families with a high probability of
1042 Mol Biol Rep (2012) 39:1037–1046
123carrying BRCA1 mutations in our population, we combined
our results with those of a previously-published study about
the contribution of BRCA mutations to breast cancer in
Tunisia [34]. Three out the 36 families studied in this
report were excluded from our cumulative analysis (one
family had a BRCA2 mutation and two families presented
male breast cancer). The stratiﬁcation of families into three
subgroups allowed a more detailed analysis. Hereditary
site-speciﬁc female breast cancer families accounted for
the large majority of this sample (69.5%; 34 out of 49
families). However, only six families were found to carry
deleterious BRCA1 mutations, accounting for the lowest
mutation frequency (17.6%, 6/34). Families presenting
bilateral breast cancer accounted only for 8% (4/49). In this
subgroup, we found that 25% (1/4) of families were
attributed to deleterious BRCA1 mutations. In contrast, a
higher rate of BRCA1 pathogenic mutations was detected in
hereditary breast/ovarian cancer families (36%, 4/11). This
subgroup accounted for 22.5% (11/49) of our sample.
When taking the affected relative number into account, we
noticed that among mutation carriers only 36% had three or
more affected relatives. These observations are not in
agreement with previous studies showing that the fre-
quency of the mutation increased with the number of
affected family members.
Most studies on different populations indicate that the
frequency of BRCA1 mutations is higher in early onset
breast cancer and that the mutation carriers are relatively
younger than those non-mutation carriers at the age of
cancer diagnosis [62, 63]. In this cumulative analysis, we
notiﬁed that there was no signiﬁcant difference between
BRCA1 mutation carriers and non-carriers at the age of
cancer diagnosis (46 vs. 43.8 years).
Interestingly, among carriers, the mean age of cancer
diagnosis was more than a decade lower in the breast
cancer families than in the breast-ovarian cancer families
(43 vs. 53.5 years). These results suggest that, in the
Tunisian population, the presence of ovarian cancer, is
more important than the family scale in the prediction of
BRCA1 mutations and that diagnosis age\45 years may be
a useful tool to distinguish breast (but not ovarian) cancer
families having a greater likelihood of carrying BRCA1
mutations.
Our cumulative mutation analysis showed that in 77% of
the affected families, the disease could not be explained by
BRCA1 mutations and that the lowest rates occurred in
breast cancer families (17% in site-speciﬁc breast cancer
and 25% in bilateral breast cancer). This indicates that
more efforts are necessary to better understand which kind
of families should be more appropriately considered for
BRCA1 screening, particularly among those characterized
by more than three female breast cancer cases. This also
indicates that BRCA2 screening in these families should
take priority, and also suggests that low penetrance genes
are likely to contribute to susceptibility to hereditary
breast/ovarian cancer in Tunisia [64].
In summary, our data extend the previous ones about
hereditary breast and ovarian cancer in Tunisia and high-
lighted the importance of the ﬁrst major breast cancer
susceptibility gene in the aetiology of breast cancer in our
population. Our study revised the frequency of deleterious
BRCA1 mutations and consistently enlarged its spectrum
in Tunisia. These studies seem to indicate that the BRCA1
mutational spectrum is rather broad and heterogeneous in
the Tunisian population. Some of these mutations appear
speciﬁc and recurrent or founding ones and also reﬂect
the existence of multiple distinct founders. In the cur-
rent study, we described for the ﬁrst time an example
of a founder mutation in the Tunisian population
(c.798_799delTT). Our cumulative mutation analysis
showed that genetic testing of Tunisian high-risk breast
cancer patients should be ﬁrst targeted to BRCA1 gene’s
exons 5, 11 and 20 where all identiﬁed mutations are
located and where it is about 23% more likely to detect a
mutation. In the Tunisian population, the likelihood of
ﬁnding a BRCA1 mutation is higher in breast-ovarian
cancer families (36%). Early-onset and bilateral breast
cancer, regardless of the family scale, may also be useful
tools to distinguish breast cancer families having a greater
likelihood of carrying BRCA1 mutations with an 18.4%
detection rate.
To conclude, the identiﬁcation of speciﬁc and recur-
rent/founder mutations suggests that any given population
should develop a mutation database for its programme of
breast cancer screening. It is very important to col-
lect more national data concerning BRCA1 mutations in
order to get the best estimation of the mutation distri-
bution (especially for recurrent/founder mutations) but it
is also important to evaluate if there are any regional
differences even in a small country like Tunisia. It is
also hoped that similar mutation surveys in other North
African countries are completed so that the information
can be compared and the most common mutations,
playing a role in the pathogenesis of breast carcinoma,
identiﬁed. This will facilitate genetic testing throughout
the region.
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